AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00706121
Drug: selenium placebo
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill by mouth daily for 7 - 12 years
Trial: NCT00145431
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00145431
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00145431
Drug: fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02575092
Drug: Enalapril Maleate Tablets(as the program-based antihypertension)
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02508311
Drug: Oral Albuterol Extended Release
RxNorm normalized name: albuterol Extended Release Oral Tablet
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
Trial: NCT00448539
Drug: Rufinamide
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
Trial: NCT02103439
Drug: Algeron
RxNorm normalized name: Algeron
DrugBank: Cepeginterferon alfa-2B (DB12814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Trial: NCT02103439
Drug: PegIntron
RxNorm normalized name: PegIntron
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 µg/kg of body weight subcutaneously, once a week
Trial: NCT00026533
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00695903
Drug: daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daptomycin 10 mg/kg IV every 24 hours
Trial: NCT00695903
Drug: vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
Trial: NCT01107574
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
Trial: NCT00849251
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00849251
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT01827059
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125-mg orange-white, round, biconvex, film-coated tablets
Trial: NCT00314652
Drug: Buprenorphine transdermal delivery system
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00417937
Drug: azelaic acid 15% gel
RxNorm normalized name: AZELAIC ACID 15% GEL,TOP
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15% gel, topically applied once daily for six weeks
Trial: NCT00417937
Drug: azelaic acid 15% gel
RxNorm normalized name: AZELAIC ACID 15% GEL,TOP
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15% gel, topically applied twice daily for six weeks
Trial: NCT01343368
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
Trial: NCT01015742
Drug: Stem cell Transplantation
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant.
Trial: NCT02794402
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bydureon (Exenatide once weekly) injections s.c.
Trial: NCT01178151
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg daily orally
Trial: NCT00726752
Drug: Axitinib (AG-013736)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
Trial: NCT00738777
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg,QD,PO
Trial: NCT00738777
Drug: Anastrozole+Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
Trial: NCT00738777
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
Trial: NCT02123654
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02123654
Drug: Asunaprevir
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02123654
Drug: DCV 3DAA
RxNorm normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01850680
Drug: sarilumab SAR153191 (REGN88)
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT02702518
Drug: rhDNase I
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT00043420
Drug: PF-3512676
RxNorm normalized name: PF-3512676 free acid
DrugBank: Agatolimod (DB15018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Trial: NCT01138904
Drug: irinotecan, oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OXIR: FOLFOX -\> FOLFIRI~IROX: FOLFIRI -\> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks
Trial: NCT01138904
Drug: oxaliplatin, irinotecan
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks
Trial: NCT00000893
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000893
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03137134
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib in a coated microsphere formulation
Trial: NCT03137134
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor, esomeprazole
Trial: NCT03006250
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
Trial: NCT03006250
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
Trial: NCT02049073
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
Trial: NCT02049073
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 32 mg or 64 mg pill administered orally once
Trial: NCT03108924
Drug: Gefapixant
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
Trial: NCT01512862
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Trial: NCT01194960
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
Trial: NCT01194960
Drug: TroVax
RxNorm normalized name: Trovax
DrugBank: OXB-301 (DB19269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
Trial: NCT00868439
Drug: patiromer
RxNorm normalized name: Patiromer
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active investigational drug
Trial: NCT02347761
Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer
RxNorm normalized name: clozapine
DrugBank: SUN-101 (DB17238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
Trial: NCT02347761
Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer
RxNorm normalized name: MyoGesic-CS
DrugBank: SUN-101 (DB17238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
Trial: NCT00001430
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322671
Drug: Reference Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
Trial: NCT02322671
Drug: Test 1 Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Trial: NCT02322671
Drug: Test 2 Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Trial: NCT01670656
Drug: Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
Trial: NCT00476476
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally every day for about 4-6 weeks
Trial: NCT02995772
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy with chemotherapy
Trial: NCT02995772
Drug: FAC
RxNorm normalized name: Ebufac
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of efficacy with hormonal therapy
Trial: NCT04301336
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
Trial: NCT04301336
Drug: Hydroxy Urea
RxNorm normalized name: alpha hydroxy acids / urea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
Trial: NCT04301336
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
Trial: NCT00781300
Drug: Loteprednol Etabonate 0.5%
RxNorm normalized name: LOTEPREDNOL ETABONATE 0.5% GEL,OPH
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
Trial: NCT00781300
Drug: Dexamethasone 0.1%
RxNorm normalized name: DEXAMETHASONE 0.1% GEL,TOP
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
Trial: NCT00165841
Drug: Rabeprazole 20 mg
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rabeprazole sodium tablet 20 mg once daily
Trial: NCT02326467
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bi-weekly chlorhexidine baths
Trial: NCT03986008
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
Trial: NCT05821153
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
Trial: NCT01063816
Drug: veliparib (ABT-888)
RxNorm normalized name: ABT-925
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
Trial: NCT01063816
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be dosed on Day 1 of each cycle, intravenously.
Trial: NCT01063816
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing on Days 1 and 8 of each Cycle, intravenously.
Trial: NCT00745186
Drug: Glucagen
RxNorm normalized name: GlucaGen
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.2 mg or 1 mg Glucagen single injection
Trial: NCT00745186
Drug: Mayne Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.2 mg or 1 mg Mayne Glucagon
Trial: NCT02526758
Drug: beclomethasone
RxNorm normalized name: Beclomethasone
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02526758
Drug: formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02526758
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00243204
Drug: talabostat mesylate
RxNorm normalized name: mesylate
DrugBank: Talabostat (DB06182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00243204
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02244866
Drug: Pergoveris (FSH and LH)
RxNorm normalized name: follicle stimulating hormone
DrugBank: Lutropin alfa (DB00044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Trial: NCT02244866
Drug: Follitropin alpha (FSH)
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
Trial: NCT00937924
Drug: Meperidine, Midazolam
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00937924
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00937924
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02362490
Drug: peginterferon alpha 2a
RxNorm normalized name: peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
Trial: NCT03435133
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg oral bolus plus oral 10 mg once daily